These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39172760)

  • 1. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
    Touzeau C; Krishnan AY; Moreau P; Perrot A; Usmani SZ; Manier S; Cavo M; Martinez Chamorro C; Nooka AK; Martin TG; Karlin L; Leleu X; Bahlis NJ; Besemer B; Pei L; Stein S; Wang Lin SX; Trancucci D; Verona RI; Girgis S; Miao X; Uhlar CM; Chastain K; Garfall AL
    Blood; 2024 Dec; 144(23):2375-2388. PubMed ID: 39172760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
    Yan Y; Tu Y; Cheng Q; Zhang J; Wang E; Deng Z; Yu Y; Wang L; Liu R; Chu L; Kang L; Liu J; Li X
    J Transl Med; 2024 Nov; 22(1):1087. PubMed ID: 39614361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.
    Ishida T; Kuroda Y; Matsue K; Komeno T; Ishiguro T; Ishikawa J; Ito T; Kosugi H; Sunami K; Nishikawa K; Shibayama K; Aida K; Yamazaki H; Inagaki M; Kobayashi H; Iida S
    Int J Hematol; 2024 Nov; ():. PubMed ID: 39607603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
    Dimopoulos MA; Migkou M; Bhutani M; Ailawadhi S; Kalff A; Walcott FL; Pore N; Brown M; Wang F; Cheng LI; Kagiampakis I; Williams M; Kinneer K; Wu Y; Jiang Y; Kubiak RJ; Zonder JA; Larsen J; Sirdesai S; Yee AJ; Kumar S
    Leuk Lymphoma; 2024 Dec; 65(12):1789-1800. PubMed ID: 39404476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 10. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
    Mohan M; Monge J; Shah N; Luan D; Forsberg M; Bhatlapenumarthi V; Balev M; Patwari A; Cheruvalath H; Bhutani D; Thanendrarajan S; Dhakal B; Zangari M; Al-Hadidi S; Cooper D; Lentzsch S; van Rhee F; D'Souza A; Szabo A; Schinke C; Chakraborty R
    Blood Cancer J; 2024 Mar; 14(1):35. PubMed ID: 38443345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
    Merz M; Dima D; Hashmi H; Ahmed N; Stölzel F; Holderried TAW; Fenk R; Müller F; Tovar N; Oliver-Cáldes A; Rathje K; Davis JA; Fandrei D; Vucinic V; Kharboutli S; Baermann BN; Ayuk F; Platzbecker U; Albici AM; Schub N; Schmitz F; Shune L; Khouri J; Anwer F; Raza S; McGuirk J; Mahmoudjafari Z; Green K; Khandanpour C; Teichert M; Jeker B; Hoffmann M; Kröger N; von Tresckow B; de Larrea CF; Pabst T; Abdallah AO; Gagelmann N
    Blood Cancer J; 2024 Dec; 14(1):214. PubMed ID: 39632797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Gong J; Hilder BW; Masterson T; Tolbert J; Renaud T; Heuck C; Kane C; De Zwart L; Girgis S; Ma X; Ouellet D
    Target Oncol; 2024 Nov; 19(6):965-979. PubMed ID: 39285155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
    Maruyama D; Jacobsen E; Porcu P; Allen P; Ishitsuka K; Kusumoto S; Narita T; Tobinai K; Foss F; Tsukasaki K; Feldman T; Imaizumi Y; Izutsu K; Morishima S; Yamauchi N; Yuda J; Brammer JE; Kawamata T; Ruan J; Nosaka K; Utsunomiya A; Wang J; Zain J; Kakurai Y; Yamauchi H; Hizukuri Y; Biserna N; Tachibana M; Inoue A; Horwitz SM
    Lancet Oncol; 2024 Dec; 25(12):1589-1601. PubMed ID: 39486432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.
    Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W
    Front Immunol; 2024; 15():1435934. PubMed ID: 39606226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial.
    Chen N; Pu C; Zhao L; Li W; Wang C; Zhu R; Liang T; Niu C; Huang X; Tang H; Wang Y; Yang H; Jia B; Jiang X; Han G; Wang W; Chen D; Wang Y; Rowinsky EK; Kennedy E; Lu VX; Cui G; Wu Z; Xiao L; Cui J
    JAMA Oncol; 2024 Nov; 10(11):1532-1536. PubMed ID: 39298141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.